Meharry Medical College, located in Nashville, Tennessee, United States, is a graduate and professional institution affiliated with the United Methodist Church whose mission is to educate healthcare professionals and scientists. Founded in 1876 as the Medical Department of Central Tennessee College, it was the first medical school in the South for African Americans, though not the first medical school for African-Americans in the nation; the Howard University College of Medicine was chartered in 1868, for example.Meharry Medical College was chartered separately in 1915. It is currently the largest private historically black institution in the United States solely dedicated to educating healthcare professionals and scientists.Meharry Medical College includes a medical school, dental school, graduate school, and an allied health school. The degrees that Meharry offers include Doctor of Medicine , Doctor of Dental Surgery , Master of Science in Public Health , Master of Science , and Doctor of Philosophy degrees. Meharry is the second largest educator of African-American medical doctors and dentists in the United States. Also, it is the largest producer of African Americans with Masters in Public Health and Ph.D.s in biomedical science.Journal of Health Care for the Poor and Underserved is a public health journal owned by and edited at Meharry Medical College. Wikipedia.
News Article | May 19, 2017
The International Association of HealthCare Professionals is pleased to welcome Dr. Teethena C. Cooper, MD, Anesthesiologist to their prestigious organization with her upcoming publication in The Leading Physicians of the World. Dr. Teethena C. Cooper is a highly trained and qualified physician with a vast expertise in all facets of her work. She has been in practice for more than seven years and is currently serving patients within Good Samaritan Hospital in Mount Vernon, Illinois. Dr. Cooper’s career in medicine began in 2009 when she graduated from Meharry Medical College in Nashville, Tennessee. Upon receiving her Medical Degree, she completed a residency at the University of Chicago. Dr. Cooper is certified by the American Board of Anesthesiology, and is a distinguished member of the Illinois Society of Anesthesiologists. She says that her success is thanks to her drive to serve and help the underprivileged in society, and when she is not working Dr. Cooper enjoys traveling to Australia and Europe, and particularly enjoys visiting Paris. Learn more about Dr. Cooper here: http://www.ssmhealthillinois.com/physicians/teethena-c-cooper-md and be sure to read her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit http://www.findatopdoc.com
News Article | June 6, 2017
"I look forward to working alongside these impressive leaders," said Marion McCourt, president and chief operating officer. "We are building an executive team of forward thinking industry leaders with proven track records and decades of experience. Known for their flawless execution, these individuals will help take Axovant to our next stage of growth." Mr. Mohr joins Axovant with over 25 years of experience in pharmaceutical legal and compliance matters. He was previously U.S. General Counsel and Deputy General Counsel, North America at AstraZeneca. Prior to assuming that position, he was Global Compliance Officer for AstraZeneca. He also held a number of senior legal and compliance positions at Bristol-Myers Squibb Company, including Vice President and Senior Counsel, U.S. Medicines. Earlier in his career, he specialized in litigation matters at Weiss David Fross Zelnick & Lehrman, P.C. (now Fross Zelnick Lehrman & Zissu) and Rivkin Leff Sherman & Radler (now Rivkin Radler LLP). Mr. Mohr holds a B.A. from Yale University and a J.D. from the University of Virginia School of Law. Dr. Floyd joins Axovant with nearly 20 years of regulatory experience within the pharmaceutical industry. Most recently, he was president of compliance services and chief scientific officer at Dohmen Life Science Services, Inc. He was SVP, US Regulatory Affairs and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon and VP and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis and held senior leadership roles at Bristol Myers Squibb, Aventis and Merck Research Laboratories. Dr. Floyd holds a B.S. from the University of Illinois, an M.S. from Tennessee State University, an M.B.A. from St. Joseph's University, Philadelphia, and a Ph.D. from Meharry Medical College, Nashville. Dr. Templeman joins Axovant with over 25 years of experience across various aspects of pharmaceutical operations. He most recently served as chief operations officer at Graybug Vision, and was senior vice president of pharmaceutical operations and quality at Medivation prior to that. He previously held positions of increasing responsibility at Hospira, Inc., Liquidia Technologies, and the Johnson & Johnson companies Centocor Biologics and Ortho Clinical Diagnostics. Dr. Templeman holds a B.S. from the University of Santa Clara and a Ph.D. from Dartmouth College. Mr. Wadley joins Axovant with 24 years of commercial leadership experience across sales, marketing, payer access and commercial operations. Mr. Wadley most recently served as senior vice president of sales at Guardant Health and previously was Vice President Oncology Sales, Organized Customers, and Payer at Medivation. He has also held various roles of increasing responsibility at Amgen, Wyeth BioPharma and Genetics Institute. Mr. Wadley holds a B.S. from Arizona State University. Ms. Bari joins Axovant with over 25 years of U.S. and global communications experience in the healthcare and pharmaceutical industries. Most recently, she was vice president of corporate communications at Medivation, and was senior vice president of corporate communications at Pharmacyclics prior to that. She has also held positions of increasing responsibility at Ikaria, Johnson & Johnson and Pfizer, in addition to having held senior-level positions at several of the world's leading global communications firms. She began her career at a New York teaching hospital. Ms. Bari holds a B.A. and M.A. from New York University. In addition, current executive team member Dr. Shankar Ramaswamy will take on a new role at Axovant as vice president, global medical affairs. Dr. Ramaswamy was one of the earliest employees of Axovant and has served the company in multiple roles, including most recently as vice president, medical and scientific communications. He was also involved in the scientific evaluation of new assets for Axovant. Dr. Ramaswamy holds an A.B. from Harvard University and a M.D. from Brown University. Mark A. Demitrack, M.D., joins Axovant as vice president, clinical research with over 25 years of academic and industry experience. Most recently, he was vice president and chief medical officer at Neuronetics. He previously held positions of increasing responsibility at Wyeth Pharmaceuticals, Lilly Research Laboratories, and University of Michigan. Dr. Demitrack holds a B.A. from Columbia University and an M.D. from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey. Richard O'Neal, R.Ph., joins Axovant as vice president of payer, access and reimbursement with more than 20 years of experience in U.S. payer and reimbursement. Most recently, he was executive director of national accounts at Amgen. He also held positions of increasing responsibility at Express Scripts, Inc. Prior to that, he was a pharmacy manager at Walgreen's Pharmacy. He holds a B.S. from the St. Louis College of Pharmacy and an M.B.A. from Lindenwood University in Missouri. Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of late- and early-stage product candidates that focuses on the cognitive, functional, and behavioral aspects of debilitating conditions such as Alzheimer's disease and Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com. This press release contains forward-looking statements, including statements regarding Axovant's clinical development and regulatory strategy for intepirdine and nelotanserin. Forward-looking statements can be identified by the words "believe," "anticipate," "continue," "estimate," "project," "expect," "plan," "potential," "intend," "will," "would," "could," "should" or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of intepirdine and nelotanserin; and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Axovant's views of the clinical study data. In addition, promising interim results or other preliminary analyses do not in any way ensure that later or final results in a clinical trial or in related or similar clinical trials will replicate those interim results. The product discussed is investigational and not approved and there can be no assurance that the clinical program for intepirdine or nelotanserin will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our product candidates will ever receive regulatory approval or be successfully commercialized. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Axovant's business in general, see the "Risk Factors" section of our quarterly report on Form 10-Q filed with the Securities and Exchange Commission on February 14, 2017, and other filings that Axovant makes with the SEC from time to time. These forward-looking statements are based on information available to Axovant as of the date of this press release and speak only as of the date of this release. Axovant disclaims any obligation to update these forward-looking statements, except as may be required by law. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/axovant-strengthens-executive-team-with-key-management-appointments-300469322.html
News Article | June 15, 2017
The International Association of HealthCare Professionals is pleased to welcome Angela Wright Brown, MD, Dentist, to their prestigious organization with her upcoming publication in The Leading Physicians of the World. Dr. Angela Wright Brown is a highly trained and qualified dentist with an extensive expertise in all facets of her work. She has been in practice for more than two decades and is currently serving patients within her own private practice, Healthy Smiles, located in Huntsville, Alabama. Dr. Brown’s career in dentistry began in 1996 when she graduated with her Doctor of Dental Surgery Degree from Meharry Medical College in Nashville, Tennessee. Following her graduation, she served as Chief Resident of Hospital Dentistry at Meharry Medical College. As a board certified dentist, Dr. Brown maintains professional memberships with several leading dental organizations, including the American Dental Association. With the support of her expert team, she provides a comprehensive range of cosmetic and general dental services. Dr. Brown attributes her success to her strong faith, and in her free time, she enjoys reading, cooking, traveling, and spending time with her family. Learn more about Dr. Brown here: http://www.healthysmileshuntsville.com/ and be sure to read her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit http://www.findatopdoc.com
News Article | June 1, 2017
Nissan partners with Meharry Medical College on educational visit for residents in Preventive and Occupational Medicine - Mathews Nissan Is Proud to Be A Part Of The Nissan Brand & Educational Partnership.. visit us online.....
Whitty J.E.,Meharry Medical College
Clinical Obstetrics and Gynecology | Year: 2010
Women with cystic fibrosis (CF) are living to childbearing age and many have successful pregnancies. Preconception care with optimization of pulmonary function, eradication of pulmonary infection, improved nutritional status, and diabetes care improve fertility and pregnancy outcome. Women with CF, poor pulmonary function and nutrition, and less than ideal body weight are more likely to suffer adverse outcomes. Women with CF and pulmonary hypertension risk mortality. Individuals with CF and end stage lung disease have improved survival after lung transplant. Women with lung transplants can have successful pregnancy, but the risk of organ rejection and death are high. © 2010, Lippincott Williams & Wilkins.
Nowicki B.,Meharry Medical College
Advances in experimental medicine and biology | Year: 2013
In this chapter, we present a concise historic prospective and a summary of accumulated knowledge on steroid hormones, DAF expression, and therapeutic implication of steroid hormone treatment on multiple pathologies, including infection and the host-pathogen interactions. DAF/CD55 plays multiple physiologic functions including tissue protection from the cytotoxic complement injury, an anti-inflammatory function due to its anti-adherence properties which enhance transmigration of monocytes and macrophages and reduce tissue injury. DAF physiologic functions are essential in many organ systems including pregnancy for protection of the semiallogeneic fetus or for preventing uncontrolled infiltration by white cells in their pro- and/or anti-inflammatory functions. DAF expression appears to have multiple regulatory tissue-specific and/or menstrual cycle-specific mechanisms, which involve complex signaling mechanisms. Regulation of DAF expression may involve a direct or an indirect effect of at least the estrogen, progesterone, and corticosteroid regulatory pathways. DAF is exploited in multiple pathologic conditions by pathogens and viruses in chronic tissue infection processes. The binding of Escherichia coli bearing Dr adhesins to the DAF/CD55 receptor is DAF density dependent and triggers internalization of E. coli via an endocytic pathway involving CD55, lipid rafts, and microtubules. Dr+ E. coli or Dr antigen may persist in vivo in the interstitium for several months. Further understanding of such processes should be instrumental in designing therapeutic strategies for multiple conditions involving DAF's protective or pathologic functions and tailoring host expression of DAF.
Borza D.-B.,Meharry Medical College
Frontiers in Immunology | Year: 2016
Membranous nephropathy (MN), a major cause of nephrotic syndrome, is a non-inflammatory immune kidney disease mediated by IgG antibodies that form glomerular subepithelial immune complexes. In primary MN, autoantibodies target proteins expressed on the podocyte surface, often phospholipase A2 receptor (PLA2R1). Pathology is driven by complement activation, leading to podocyte injury and proteinuria. This article overviews the mechanisms of complement activation and regulation in MN, addressing the paradox that anti-PLA2R1 and other antibodies causing primary MN are predominantly (but not exclusively) IgG4, an IgG subclass that does not fix complement. Besides immune complexes, alterations of the glomerular basement membrane (GBM) in MN may lead to impaired regulation of the alternative pathway (AP). The AP amplifies complement activation on surfaces insufficiently protected by complement regulatory proteins. Whereas podocytes are protected by cell-bound regulators, the GBM must recruit plasma factor H, which inhibits the AP on host surfaces carrying certain polyanions, such as heparan sulfate (HS) chains. Because HS chains present in the normal GBM are lost in MN, we posit that the local complement regulation by factor H may be impaired as a result. Thus, the loss of GBM HS in MN creates a micro-environment that promotes local amplification of complement activation, which in turn may be initiated via the classical or lectin pathways by subsets of IgG in immune complexes. A detailed understanding of the mechanisms of complement activation and dysregulation in MN is important for designing more effective therapies. © 2016 Borza.
Sheng L.,Meharry Medical College
Toxicological sciences : an official journal of the Society of Toxicology | Year: 2010
Gene by environment interactions (G × E) are thought to underlie neurodevelopmental disorder, etiology, neurodegenerative disorders, including the multiple forms of autism spectrum disorder. However, there is limited biological information, indicating an interaction between specific genes and environmental components. The present study focuses on a major component of airborne pollutants, polycyclic aromatic hydrocarbons (PAHs), such as benzo(a)pyrene [B(a)P], which negatively impacts cognitive development in children who have been exposed in utero. In our study, prenatal exposure of Cpr(lox/lox) timed-pregnant dams to B(a)P (0, 150, 300, and 600 μg/kg body weight via oral gavage) on embryonic day (E14-E17) consistent with our susceptibility-exposure paradigm was combined with the analysis of a replicated autism risk gene, the receptor tyrosine kinase, Met. The results demonstrate a dose-dependent increase in B(a)P metabolite generation in B(a)P-exposed Cpr(lox/lox) offspring. Additionally, a sustained persistence of hydroxy metabolites during the onset of synapse formation was noted, corresponding to the peak of Met expression. Prenatal B(a)P exposure also downregulated Met RNA and protein levels and dysregulated normal temporal patterns of expression during synaptogenesis. Consistent with these data, transcriptional cell-based assays demonstrated that B(a)P exposure directly reduces human MET promoter activity. Furthermore, a functional readout of in utero B(a)P exposure showed a robust reduction in novel object discrimination in B(a)P-exposed Cpr(lox/lox) offspring. These results confirm the notion that common pollutants, such as the PAH B(a)P, can have a direct negative impact on the regulated developmental expression of an autism risk gene with associated negative behavioral learning and memory outcomes.
News Article | February 27, 2017
Bishop Joseph W. Walker, III, senior pastor of Mount Zion Baptist Church, will bring his inspirational message of hope to millions; the program will launch Sunday, March 5 at 6:30 a.m. EST/5:30 a.m. CST NASHVILLE, TN--(Marketwired - Feb 27, 2017) - Bishop Joseph W. Walker, III, Nashville-based Senior Pastor of Mount Zion Baptist Church and Presiding Bishop of Full Gospel Baptist Fellowship International, will become the new featured minister on Black Entertainment Television (BET), called "The Relevant Word." He will be bringing his message of hope in Jesus Christ to homes across the country beginning Sunday, March 5. Bishop Walker follows in the footsteps of other influential black ministers who have regularly hosted programs on BET. Bishop Walker's theme, explored weekly, will be "hope" and his messages will encourage listeners to believe in a better life and a better world regardless of circumstances -- whether economic hardship, political turmoil, mental anxiety, or physical illness. Bishop Walker will help listeners gain a greater understanding of the biblical definition of hope as a "confident expectation" that, even though aspects of life are unknown and unclear, we are born to fulfill a true destiny. "I am so honored to be the featured minister for 'The Relevant Word,' and I'm extremely grateful to BET for giving me this national platform to make a difference in people's lives," said Bishop Walker. "Most importantly, I am eager to encourage listeners across the country to live in hope. Through Jesus Christ, we can come to view the uncertainties of life in a more positive light, believing that God has a greater purpose for us." A native of Shreveport, Louisiana, Walker received a Bachelor's degree from Southern University in Baton Rouge; a Master of Divinity degree from Vanderbilt University and a Doctor of Ministry degree from Princeton Theological University. He also holds two honorary Doctorates from Meharry Medical College and Southern University. At the age of 24, Bishop Walker began his pastorate at Mount Zion with just 175 members. Today, the ministry stands at more than 30,000 souls with three locations in the Nashville area. Bishop Walker's stirring oratory and pastoral approach draw people of every age and from every walk of life to the Word of God. The Relevant Word set to premiere on March 5, 2017 and will air every Sunday at 6:30 a.m. EST/5:30 a.m. CST. For more information on Bishop Walker and Mount Zion Baptist Church, please visit, www.mtzionnashville.org About Mt. Zion Baptist Church Mount Zion Baptist Church is a Word-centered ministry designed to evangelize the lost at any cost, equip and empower the people of God and provide holistic ministry to our community as well as the world. Seeking to minister to the total person, we are a multi-ethnic, multi-cultural ministry impacting the world in which we live with the uncompromising message of Jesus Christ. Committed to the spirit of excellence, we are striving to become an oasis of hope within the Nashville community by promoting and providing education and awareness, as well as financial independence. Mount Zion Baptist Church is one church located in the three locations and accessible virtually anywhere via mtzionanywhere.org to millions around the world.
News Article | February 16, 2017
The International Association of HealthCare Professionals is pleased to welcome Dana Aubert Truesdale, DDS, Dentist to their prestigious organization with her upcoming publication in The Leading Physicians of the World. Dr. Dana Aubert Truesdale is a highly trained and qualified dentist with an extensive expertise in all facets of her work, especially general, family, and cosmetic dentistry. Dr. Truesdale has been in practice for 13 years and is currently serving patients within her own private practice, Innovation Dental Center, located in Baltimore, Maryland. Dr. Truesdale attended Meharry Medical College School of Dentistry in Nashville, Tennessee, graduating with her Doctor of Dental Surgery Degree in 2004. Following her graduation, Dr. Truesdale subsequently completed her residency at the University of Mississippi Medical Center in Jackson, Mississippi. In addition to her clinical practice, Dr. Truesdale serves as Captain in the United States Army National Guard, and received a Diploma of Ministerial Studies from the Spirit of Faith Bible Institute. She is a Certified Provider in Clear Correct and 6 Month Smiles, and attributes her success to her parents, her upbringing, and her life experiences. Dr. Truesdale is a member of the Dream Makers Network Foundation, which encourages personal self-development, and is also a Community Service Advocate. She is very passionate about serving others and helping them achieve healthy, beautiful smiles, and was recognized as one of Baltimore’s Top 3 Dentists. In her free time, Dr. Truesdale enjoys traveling. Learn more about Dr. Truesdale here: http://innovationdentalbaltimore.com/ and be sure to read her upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit http://www.findatopdoc.com